Table 4. Comparisons of the available meta-analyses evaluating the relationship between testosterone therapy and CV risk.

Variable	Study
	Calof et al (2005) [49]		Haddad et al (2007) [50]		Fernández-Balsells et al (2010) [51]		Xu et al (2013) [52]		Corona et al (2014) [53]		Borst et al (2014) [54]		Albert and Morley (2016) [55]		Alexander et al (2017) [56]
No. of trials included	19		30		51		27		75		35		45		39
No. of patients analyzed	1,084		1,642		2,679		2,944		5,464		3,703		5,328		5,441
Inclusion criteria	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
Primary end point MACE incidence		×		×		×		×	×			×		×		×
Primary end point CV event other than MACE	×		×		×		×			×	×		×		×
Time restriction (>12 wk)	×			×		×		×		×		×		×		×
Age restriction (≥45 y)	×			×		×		×		×		×		×		×
CV event analysis
All CV events	×		×			×	×		×		×		×			×
Serious adverse events		×		×		×	×			×		×		×		×
(including MACE)
MACE		×		×		×		×	×			×		×		×
AMI	×		×		×			×	×			×		×	×
Acute coronary syndrome	×			×		×		×	×			×		×		×
Coronary by-pass surgery	×			×	×			×	×			×		×		×
Stroke	×			×		×		×	×			×		×	×
New heart failure		×		×		×		×	×			×		×		×
Arrhythmias	×			×	×			×	×			×		×		×
CV mortality		×		×		×	×		×			×		×
Overall mortality		×		×		×		×		×		×		×	×

X indicates if Yes or No. CV: cardiovascular, MACE: major adverse cardiovascular events, AMI: acute myocardial infarction.